Outpatient versus inpatient intravenous diuretic therapy for heart failure in the United States

Eur J Heart Fail. 2022 Nov;24(11):2199-2202. doi: 10.1002/ejhf.2727. Epub 2022 Nov 15.

Authors

Stephen J Greene^{1

2}, Daisuke Goto³, Dong Wang³, Robert Hilkert³, Dominik Lautsch³, Gregg C Fonarow⁴

Affiliations

¹ Duke Clinical Research Institute, Durham, NC, USA.
² Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
³ Merck & Co., Inc., Rahway, NJ, USA.
⁴ Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles, Los Angeles, CA, USA.

PMID: 36334074
DOI: 10.1002/ejhf.2727

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Intravenous
Diuretics* / therapeutic use
Heart Failure* / drug therapy
Humans
Inpatients
Outpatients
United States / epidemiology

Substances

Diuretics